Psychiatr Prax 2006; 33(2): 93-94
DOI: 10.1055/s-2005-866987
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Umstellung von Clozapin auf Quetiapin ohne Rebound-Psychose

No Rebound Psychosis in a Case of Switching from Clozapine to QuetiapineSebastian  Walther1 , Dan  Baciu1
  • 1Universitäre Psychiatrische Dienste Bern, Schweiz
Further Information

Publication History

Publication Date:
24 February 2006 (online)

Zusammenfassung

Anliegen: Nach raschem Absetzen von Clozapin treten häufig Rebound-Psychosen auf. Mögliche Ursachen sind die veränderte Affinität des D2-Rezeptors und eine verstärkte Dopaminausschüttung. Methodik: Wir berichten einen Fall, der mit Clozapin und Aripiprazol behandelt wurde und bei dem man Clozapin abrupt absetzte. Clozapin wurde durch Quetiapin substituiert. Ergebnisse: Über einen Zeitraum von zehn Wochen trat keine Rebound-Psychose auf. Schlussfolgerungen: Die Kombination aus Aripiprazol und Quetiapin schien die Dopaminhypersensitivität am D2-Rezeptor wirkungsvoll ausgleichen zu können.

Abstract

Objective: After rapid discontinuation of clozapine treatment rebound psychosis have been reported. Preexposure of D2 receptors to clozapine may alter their affinity to endogenous dopamine. Clozapine withdrawal may also lead dysfunctional NMDA-receptors to cause dopamine release in the striatum. Method: We report a case of a schizophrenic patient treated with clozapine 200 mg and aripiprazole 15 mg per day. After rapid clozapine discontinuation we added quetiapine up to 700 mg daily. Results: No rebound psychosis occurred. Even ten weeks after switching to quetiapine the patient's condition remained stable in the Brief Psychiatric Rating Scale. Conclusions: The combination of aripiprazole and quetiapine seemed to control supersensitivity effects at the D2 receptor after clozapin withdrawal in this case.

Literatur

  • 1 Ekblom B, Eriksson K, Lindstrom L H. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal.  Psychopharmacology (Berl). 1984;  83 293-294
  • 2 Parsa M A, Lahham Y H al, Ramirez L F, Meltzer H Y. Prolonged psychotic relapse after abrupt clozapine withdrawal.  J Clin Psychopharmacol. 1993;  13 154-155
  • 3 Shiovitz T M, Welke T L, Tigel P D, Anand R, Hartman R D, Sramek J J, Kurtz N M, Cutler N R. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal.  Schizophr Bull. 1996;  22 591-595
  • 4 Stanilla J K, Leon J de, Simpson G M. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases.  J Clin Psychiatry. 1997;  58 252-255
  • 5 Leon J de, Stanilla J K, White A O, Simpson G M. Anticholinergics to treat clozapine withdrawal.  J Clin Psychiatry. 1994;  55 119-120
  • 6 Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.  Am J Psychiatry. 1999;  156 876-884
  • 7 Coyle J T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?.  Biochem Pharmacol. 2004;  68 1507-1514
  • 8 Tsai G E, Yang P, Chung L C, Tsai I C, Tsai C W, Coyle J T. D-Serine added to clozapine for the treatment of schizophrenia.  Am J Psychiatry. 1999;  156 1822-1825
  • 9 Javitt D C, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.  Mol Psychiatry. 2005;  10 275-287
  • 10 Williams J B, Mallorga P J, Jeffrey C P, Pettibone D J, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters.  Schizophr Res. 2004;  71 103-112
  • 11 Javitt D C, Hashim A, Sershen H. Modulation of striatal dopamine release by glycine transport inhibitors.  Neuropsychopharmacology. 2005;  30 649-656
  • 12 Kumar V, Brecher M. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients.  J Clin Psychiatry. 1999;  60 (suppl 13) 5-9
  • 13 Gründer G, Carlsson A, Wong D F. Mechanism of new antipsychotic medications: occupancy is not just antagonism.  Arch Gen Psychiatry. 2003;  60 974-977
  • 14 Swainston H T, Perry C M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.  Drugs. 2004;  64 1715-1736
  • 15 Mass R, Burmeister J, Krausz M. Dimensionale Struktur der deutschen Version der Brief Psychiatric Rating Scale (BPRS).  Nervenarzt. 1997;  68 239-244

Dr. med. Sebastian Walther

Universitäre Psychiatrische Dienste Bern

Bolligenstraße 111

3000 Bern 60 · Schweiz

Email: Sebastian.Walther@gef.be.ch

    >